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Abstract: Although advanced age or symptoms of aging are not among approved indications 
for growth hormone (GH) therapy, recombinant human GH (rhGH) and various GH-related 
products are aggressively promoted as anti-aging therapies. Well-controlled studies of the effects 
of rhGH treatment in endocrinologically normal elderly subjects report some improvements in 
body composition and a number of undesirable side effects in sharp contrast to major beneﬁ  ts 
of GH therapy in patients with GH deﬁ  ciency. Controversies surrounding the potential utility of 
GH in treatment of a geriatric patient are fueled by increasing evidence linking GH and cancer 
and by remarkably increased lifespan of GH-resistant and GH-deﬁ  cient mice. Conservation 
of cellular signaling mechanisms that inﬂ  uence aging in organisms ranging from worms to 
mammals suggests that at least some of the results obtained in mutant mice are applicable to 
the human. We suggest that the normal, physiological functions of GH in promoting growth, 
sexual maturation and fecundity involve signiﬁ  cant costs in terms of aging and life expectancy. 
Natural decline in GH levels during aging likely contributes to concomitant alterations in body 
composition and vigor but also may be offering important protection from cancer and other 
age-associated diseases.
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Introduction
Last year, Liu and colleagues (2007) reported results of meta analysis of ﬁ  ndings from a 
series of 18 studies of the use of recombinant human growth hormone (rhGH) in healthy 
elderly and concluded that the literature “to randomized, controlled trials evaluating 
GH therapy … suggest that it is associated with small changes in body composition 
and increased rates of adverse events” and that “based on this evidence, GH cannot 
be recommended as an anti-aging therapy.” Proponents of the use of rhGH as anti-
aging therapy promptly placed on the internet a lengthy rebuttal entitled “Analysis of 
faulty data yields inaccurate results” (A4M 2007). The contrast between these two 
communications illustrates the intensity of a long-standing controversy concerning 
the role of GH in the control of aging and the potential utility of GH as an anti-aging 
agent. The purpose of this article is to brieﬂ  y summarize the ﬁ  ndings that prompted 
this controversy, highlight some recent reports pertinent to this topic and propose an 
explanation for the existence of both detrimental and beneﬁ  cial effects of GH on life 
expectancy, age-related diseases and functionality during different stages of life.
Age-related decline in GH release and its functional 
implications:   The somatopause
Growth hormone levels in circulating blood are high early in life, corresponding to 
the period of rapid somatic growth, and begin to decline soon after attainment of adult 
body size and full physical and reproductive maturation. This decline continues during 
adult life and aging and consequently plasma GH levels in elderly individuals are much Clinical Interventions in Aging 2008:3(4) 660
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lower than in young adults. Age-related decline in GH levels 
is very well documented, consistent across different mam-
malian species and primarily due to reduced hypothalamic 
secretion of GH-releasing hormone (GHRH) with conse-
quent decline of GH biosynthesis and release by the anterior 
pituitary (Sonntag et al 1980; Glustina and Veldhuis 1998; 
Kuwahara et al 2004; Frutos et al 2007). This, in turn, leads to 
a reduction in circulating levels of insulin-like growth factor 1 
(IGF-1), the key mediator of GH action (Goodman-Gruen 
and Barrett-Connor 1997; Maggio et al 2006). Age-related 
decline in the activity of the somatotropic axis (GHRH, GH 
and IGF-1) has been termed “somatopause” in analogy to 
the menopause and andropause, the age-related decline in 
gonadal function and plasma levels of sex steroids in women 
and men. Because some of the symptoms of aging including 
decrease in muscle mass, increased adiposity, reduced libido 
and energy resemble symptoms of adult GH deﬁ  ciency, it 
is reasonable to conclude that somatopause accounts for or 
contributes to the development of many of these symptoms. 
This argument is strengthened by the well-documented role 
of declining levels of sex steroids in the morphological and 
functional changes that accompany aging.
Can GH therapy prevent or perhaps 
even reverse aging?
The landmark study of Rudman and colleagues (1990) 
reported that 6 months of treatment of men over 65 years 
of age who have low levels of plasma IGF-1 with rhGH 
reduced adiposity, increased muscle mass, increased bone 
mineral density in some of the examined sites of the skeleton 
and improved general well-being. These results elicited 
enormous general interest by raising the possibility of using 
hormonal replacement therapy to slow down, halt or perhaps 
even reverse aging, or at least some of its symptoms. These 
exciting possibilities were consistent with well-documented 
and often quite dramatic beneﬁ  cial effects of GH treatment 
in patients with GH deﬁ  ciency (Baum et al 1998; Shalet 
et al 2006; Arwert et al 2006) and with the ability of GH 
therapy to ameliorate age-related changes in metabolic 
characteristics, brain vascularity and cognitive function in 
old rats (Ramsey et al 2004; Sonntag et al 2005b; Groban 
et al 2006). However, studies conducted after the report of 
Rudman and colleagues (1990) indicated that treatment of 
endocrinologically normal healthy elderly individuals with 
rhGH produces generally small improvements in body 
composition along with a number of undesirable side effects 
including arthralgias, edema, carpal tunnel syndrome, insulin 
resistance and possibly also diabetes (Papadakis et al 1996; 
von Werder 1999; Blackman et al 2002; Liu et al 2007). 
Thus it appears that effects of GH replacement in young 
or middle-aged adults who developed GH deﬁ  ciency as a 
result of head trauma, pituitary tumors and/or treatment of 
cranial tumors with surgery or irradiation are difﬁ  cult to 
reproduce in elderly individuals in which GH levels are 
low due to age-related decline in the hypothalamic “drive” 
of somatotroph function. It is also difﬁ  cult to compare the 
results of randomized placebo-controlled studies to open 
label and case studies and there is considerable disagreement 
about rhGH dose levels that may have optimal risk:beneﬁ  t 
ratio in elderly subjects. Additional large, long-term studies 
are needed to arrive at ﬁ  rm conclusions about the potential 
usefulness of GH for treatment of speciﬁ  c age associated 
changes such as an increase in visceral obesity or as an 
anti-aging agent.
In the context of the ongoing controversy about the use 
of GH in geriatric “anti-aging” medicine, it should also be 
mentioned that the clinical use of rhGH is currently approved 
in the US only for treatment of GH deﬁ  ciency, idiopathic 
short stature and HIV/AIDS.
Does GH normally act to promote 
rather than prevent aging?
Mice with mutations that cause GH deficiency or GH 
resistance live longer than their genetically normal siblings 
(Table 1). This includes animals with targeted disruption of 
the GH receptor gene that blocks GH actions, ie, produces 
complete GH resistance, the so-called Laron dwarf mice 
(Coschigano et al 2003), Ames dwarf and Snell dwarf mice, 
which have defects of anterior pituitary development leading 
to the absence of GH, prolactin and thyrotropin (Brown-
Borg et al 1996; Flurkey et al 2001) and Little mice with 
isolated GH deﬁ  ciency due to mutation of the receptor for 
hypothalamic GH-releasing hormone (Flurkey et al 2001). 
The increased longevity in these mutants is striking, rang-
ing from 25% to over 60% and readily reproducible, pres-
ent in both genders and not limited to a particular inbred 
or heterogeneous genetic background or diet formulation 
(Coschigano et al 2003; Bartke and Brown-Borg 2004a; 
Bartke et al 2004b; Bartke 2006; Bonkowski et al 2006b). 
Importantly, these long-lived mutants exhibit numerous indi-
ces of delayed aging and maintain youthful appearance, vigor 
and cognitive abilities at the age at which normal animals 
exhibit signiﬁ  cant physical and functional decline (Flurkey 
et al 2001; Silberberg 1972; Kinney et al 2001a, 2001b). 
The increased “healthspan” of these mutants also includes 
reduced incidence and delayed onset of neoplastic disease, Clinical Interventions in Aging 2008:3(4) 661
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the most common cause of death in laboratory mice (Ikeno 
et al 2003; unpublished data).
These results lead to a counterintuitive but unavoidable 
conclusion that the actions of GH normally released by the 
pituitary somehow limit life expectancy and that this is accom-
panied by and likely due to acceleration of the biological 
process of aging. The conclusion that GH signaling can accel-
erate aging and shorten lifespan is strongly supported by the 
reports that reduced levels of IGF-1, partial IGF-1 resistance 
and mutations suppressing IGF-1 signaling downstream from 
the IGF-1 receptor also increase longevity of mice although 
only in females (Holzenberger et al 2003; Sell and Lorenzini 
2007; Taguchi et al 2007; Selman et al 2008). Disagreement 
between the reported effects of insulin receptor substrate 2 
(IRS2) gene deletion on mouse longevity (Taguchi et al 2007; 
Selman et al 2008) is likely related to using different diets in 
these two laboratories (Bartke 2007, 2008). Further support 
of the role of IGF-1 in aging is provided by the recent ﬁ  nd-
ings that deletion of pregnancy-associated plasma protein A 
(PAPP-A), a protease that destroys IGF-1 binding proteins, 
markedly increases longevity of mice presumably by reduc-
ing local availability of IGF-1 (Conover and Bale 2007). In 
this context, it is of interest that transgenic mice with grossly 
elevated levels of GH and IGF-1 due to overexpression of dif-
ferent GH genes are short-lived and express various symptoms 
of accelerated aging (Bartke 2003).
Phenotype of long-lived mutant 
mice:   Tradeoffs and costs of extended 
longevity
Growth hormone-resistant, hypopituitary and GH-deﬁ  cient 
mice appear normal at birth but their postnatal growth rate 
is reduced, leading to markedly diminished adult size. 
This is most pronounced in the Snell and Ames dwarfs that, 
in adulthood, weigh less than a half of the body weight of 
their normal siblings. Reduction in body weight of these 
mutants is often accompanied by increased adiposity, 
which is particularly striking in Ghr−/− (“Laron dwarf”) 
and Ghrhr−/− (“Little”) mice (Flurkey et al 2001; Berryman 
et al 2004; Bonkowski et al 2006). Interestingly, these obese 
animals do not exhibit symptoms of metabolic syndrome 
or propensity to develop type 2 diabetes. Instead, they are 
hypoinsulinemic and very sensitive to insulin actions (Borg 
et al 1995; Zhou et al 1997; Dominici et al 2002; Bonkowski 
et al 2006b). These paradoxical ﬁ  ndings have been related to 
diminished mass of pancreatic islets (Parsons et al 1995; Liu 
et al 2004), and preferential distribution of fat to subcutane-
ous depots (Berryman et al 2004; unpublished data).
In long-lived GHRKO mice, sexual maturation is delayed 
and various measures of fecundity including litter size and 
intervals between consecutive litters are reduced in compari-
son to normal animals (Chandrashekar et al 1999; Zaczek 
et al 2002; Keene et al 2002). Female Snell and Ames dwarf 
mice are infertile but this is speciﬁ  cally due to prolactin deﬁ  -
ciency (Bartke and Brown-Borg 2004a; Bartke 2006) rather 
than to reduced GH signaling. These ﬁ  ndings could be inter-
preted as evidence for “tradeoffs” between somatic growth, 
reproductive potential and longevity. It is interesting that in 
comparison to the established strains of laboratory mice that 
have been bred in captivity for over a hundred years, ie, for 
many hundreds of generations, stocks of mice derived from 
animals recently captured in their natural environment are 
characterized by reduced body size, delayed puberty, small 
litters and enhanced longevity (Harper et al 2006). One could 
speculate that selection for optimal breeding performance in 
captivity led to GH-mediated enhancement of fecundity and 
Table 1 Mutant mice with reduced somatotropic (GH/IGF-1) signaling and extended longevity
Mutation Effects on somatotropic signaling Reference
Ames dwarf; mutation of Prophet of pituitary 
factor1 (Prop1); Prop1df
Failure of somatotroph differentiation; 
GH deﬁ  ciency
Borg et al 1996
Snell dwarf; mutation of Pituitary factor 1; Pit1dw Failure of somatotroph differentiation; 
GH deﬁ  ciency
Flurkey et al 2001
Little; mutation of GH releasing hormone receptor; 
Ghrhrlit
GH deﬁ  ciency Flurkey et al 2001
Laron dwarf; Deletion of GH receptor/GH binding 
protein gene; Ghr/bp −/−
Deletion of GH receptors; GH 
resistance
Coschigano et al 2003
Midi-mice; hypomorphic IGF-1 mutation Reduced IGF-1 levels Sell and Lorenzini 2007
Heterozygous for deletion of IGF-1 receptor, Igfr +/− Partial IGF-1 resistance Holzenberger et al 2003
Deletion of Pregnancy associated plasma protein A; 
PAPP-A −/− (an IGFBP protease)
Reduced local (tissue) availability of 
IGF-1
Conover and Bale 2007
Abbreviations: GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP, insulin-like growth factor binding protein.Clinical Interventions in Aging 2008:3(4) 662
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the rate of growth and maturation at expense of accelerated 
aging, earlier onset of age-related disease and reduced life 
expectancy. Genetic manipulations and spontaneous muta-
tions that reduce GH signaling would thus restore and exag-
gerate some features of the original “wild type” phenotype. 
Many examples of trade-offs between longevity, growth and 
reproduction have been provided by studies in invertebrates 
(Partridge et al 2005).
Does the relationship of GH
and aging discovered in mice apply 
to other species?
Results obtained in natural mutant, gene knock-out and 
transgenic mice discussed earlier in this article demonstrate 
a striking negative association of somatotropic signaling 
and lifespan. Analysis of average longevity of mice from 
different strains, stocks and selected lines as well as indi-
vidual animals from a genetically heterogeneous population 
provided evidence that this association apparently applies 
also to genetically normal individuals (Roberts 1961; Rollo 
2002; Miller et al 2002). In these comparisons, adult body 
size, which can be considered a biological marker of GH 
actions, was negatively correlated with longevity. Similar 
association was reported in other species, including rats 
(Rollo 2002) and horses (Brosnahan and Paradis 2003) and 
is particularly striking in domestic dogs with small breeds 
and small individuals living much longer than large dogs 
(Patronek et al 1997; Greer et al 2007). In rats, reducing 
somatotropic signaling by transgenic expression of mis-
sense GH produced a modest but statistically signiﬁ  cant 
increase in lifespan (Shimokawa et al 2002) but longevity 
of GH-deﬁ  cient dwarf rats does not differ from their normal 
siblings (Sonntag et al 2005a). Interestingly, rats with adult 
GH deﬁ  ciency produced by treating GH-deﬁ  cient mutants 
with GH early in life and then discontinuing this treatment, 
lived longer than vehicle-injected mutants or normal controls 
(Sonntag et al 2005a).
It is not entirely clear to what extent the negative associa-
tion of adult body size with longevity applies to the human. 
Pioneering studies of Samaras and his colleagues (recently 
summarized in a book [Samaras 2007]) provided numerous 
examples of short individuals living longer than tall individu-
als from the same population. For example, in over 3,000 
professional baseball players, age at death was strongly 
negatively correlated with both height and weight (Samaras 
and Storms 2002; Samaras 2007). In contrast, some studies 
reported increased risk of cardiovascular disease and reduced 
life expectancy in short individuals (Forsen et al 2000; 
Schnaider et al 2005). There is strong evidence that tall 
individuals have increased cancer risk (Tretli 1989; Gunnell 
et al 2001; Littman et al 2007), but the relationship of stature 
to overall mortality continues to be controversial. Data spe-
ciﬁ  cally concerning the effects of GH on human longevity 
are also inconsistent. One study reported markedly reduced 
longevity of individuals with congenital GH deﬁ  ciency 
(Besson et al 2003) while other workers reported that both 
GH-deficient and GH-resistant subjects can reach very 
advanced age, are protected from cancer and, interestingly, 
are also protected from atherosclerosis and vascular pathol-
ogy in spite of obesity and unfavorable serum lipid proﬁ  les 
(Krzisnik et al 1999; Laron 2005; Menezes Oliveira et al 
2006; Shechter et al 2007; Shevah and Laron 2007). Discus-
sion of genetic, lifestyle, nutritional and socioeconomical 
factors affecting growth, adult stature, health and longevity 
in the human is beyond the scope of this brief review.
Pathological hypersecretion of GH in patients with gigan-
tism and acromegaly reduces life expectancy due to increased 
incidence of cardiovascular disease, diabetes and, in acrome-
galics, apparently also cancer (Jadresic et al 1982; Orme et al 
1998). The question whether the rate of aging is affected by 
acromegaly has apparently never been addressed. A series 
of elegant studies by Sacca and colleagues (Sacca et al 1994, 
2003) provided evidence that both GH deﬁ  ciency and GH 
excess are detrimental for cardiac function in the human 
with GH-deﬁ  cient patients beneﬁ  ting from GH therapy and 
acromegalics beneﬁ  ting from suppression of GH levels. 
Another possible reason for the complex relationship between 
somatotropic signaling and human longevity was provided by 
results of genetic studies which indicated that reduced IGF-1 
levels protect from some age-related diseases but increase 
the risk of others (Lamberts et al 1997).
Interplay of GH and aging: Current 
understanding and potential 
for anti-aging interventions
Although much of the currently available information 
concerning the role of GH in the control of human aging is 
limited in scope and inconclusive and some time are conﬂ  ict-
ing, there is every reason to believe that the results of ongo-
ing and future studies will change this situation. GH actions 
and control of somatic growth have already been related to 
aging and longevity in other mammals including rodents, 
carnivores and ungulates (details earlier in this article). GH 
has a key role in controlling biosynthesis of IGF-1 and exerts 
important direct and indirect actions on the secretion of insu-
lin and on responsiveness of target tissues to insulin actions. Clinical Interventions in Aging 2008:3(4) 663
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A major role of IGF-1, insulin and homologous molecules in 
the control of longevity has been conclusively documented 
in organisms ranging from worms and insects to mammals, 
and related mechanisms inﬂ  uence aging of unicellular yeast. 
Against the background of this information, it is difﬁ  cult to 
imagine how aging in primates or humans could prove to be 
free of the inﬂ  uence of somatotropic signaling.
How can we summarize the present understanding and 
use this information to suggest possible anti-aging interven-
tions? Physiological action of the amounts of GH normally 
secreted by the pituitary is critically needed for growth and 
maturation and enhances reproductive potential but may 
also limit life expectancy. Somatotropic signaling can be 
suppressed by modest calorie restriction (Masoro 2001). 
Well-documented beneﬁ  cial effects of calorie restriction on 
longevity of many species and on important predictors of life 
expectancy in humans (Heilbronn et al 2006; Holloszy and 
Fontana 2007) suggest that subtle, long-term reduction in GH 
release and/or activity may have a potential to slow aging, 
protect from age-related disease and increase lifespan. How-
ever, the symptoms of congenital or acquired GH-deﬁ  ciency 
clearly indicate that severe or complete suppression of GH 
actions can not be recommended or even seriously considered 
for enhancement of human longevity.
GH levels decline during aging. This natural change in 
the endocrine system most likely contributes to unwelcome 
effects of aging on body composition, skin characteristics 
and functional changes contributing to the general quality 
of life, but at the same time may offer protection from can-
cer and other age-related diseases. Thus GH replacement 
therapy is almost certain to involve both risks and beneﬁ  ts. It 
appears likely that future research will demonstrate beneﬁ  ts 
of low-dose GH therapy in some individuals with frailty 
and/or sarcopenia and clearly deﬁ  ne contraindications to GH 
therapy, for example, family history or genetic predisposi-
tion to cancer. Current debates about the use of estrogens in 
postmenopausal women and testosterone in elderly men and 
emergence of guidelines for individualized approach to sex 
steroid therapy allow the prediction of how responsible use 
of GH in geriatric medicine may eventually evolve.
After this article was written, Suh and colleagues (2008) 
described mutations of the human IGF-1 receptor which 
reduce cellular responses to IGF-1 and reported that in 
women, IGF-1 resistance is associated with shorter stature 
and extended longevity. These important ﬁ  ndings provide 
the strongest evidence available to date that reduced somato-
tropic signaling can lead to increased life expectancy in the 
human.
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